INCA-035784

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameINCA-035784
Drug Alias NameINCA035784INCA-035784
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsMyeloproliferative Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesItaly +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesIncyte Corp
China Registration ClassN/A

Develop Information

Active CompaniesIncyte Corp
Inactive CompaniesN/A
Active IndicationsMyeloproliferative Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A